natgillin/translations-raw huggingface dataset:
People with more serious rheumatoid arthritis who have had the disease for a long time may have a higher than average risk of getting lymphoma and leukaemia (cancers that affect blood cells and bone marrow). 
Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja morda povečano tveganje, da zbolijo za limfomom in levkemijo (vrsta raka, ki prizadene krvne celice in kostni mozeg).
Hulio is a biosimilar medicinal product. 
Zdravilo Hulio je podobno biološko zdravilo.
• excessive fluid around the lung; 
• čezmerna količina tekočine okrog pljuč;
No studies have been conducted that include patients with a history of malignancy or in whom treatment with adalimumab is continued following development of malignancy. 
Študije, ki bi vključevale bolnike z anamnezo malignoma ali bolnike, pri katerih bi se zdravljenje z adalimumabom nadaljevalo po pojavu malignoma, niso bile izvedene.
If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Hulio and is positive for antibodies against double-stranded DNA, further treatment with Hulio should not be given (see section 4.8). 
Če se bolniku po zdravljenju z zdravilom Hulio pojavijo simptomi, ki nakazujejo lupusu podoben sindrom, in ima pozitivna protitelesa proti dvojnoverižni DNA, zdravljenja z zdravilom Hulio ne sme nadaljevati (glejte poglavje 4.8).
Pull the plunger to 0.1 ml beyond the prescribed dose (for example, if the prescribed dose is 0.5 ml, pull the white plunger rod to 0.6 ml). 
Bat potegnite ven tako, da je 0,1 ml preko predpisanega odmerka (če je npr. predpisani odmerek 0,5 ml, potegnite beli nosilec bata do 0,6 ml).
Adalimumab showed statistically significantly greater improvement in the HAQ-S total score and the SF-36 Physical Component Score (PCS) from baseline to week 12 compared to placebo. 
Adalimumab je pokazal statistično večje izboljšanje skupnega števila točk v vprašalniku HAQ-S in točk v telesni komponenti (Physical Component Score (PCS)) v vprašalniku SF-36 od začetka do 12. tedna v primerjavi s placebom.
Administration of live vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months following the mother's last adalimumab injection during pregnancy. 
Uporaba živih cepiv (npr. BCG cepivo) pri dojenčkih, ki so bili izpostavljeni adalimumabu in utero, ni priporočljiva še 5 mesecev po materini zadnji injekciji adalimumaba med nosečnostjo.
It is important to tell your doctor if your child has had or have a serious heart condition (see “Warnings and precautions”). 
Pomembno je, da zdravniku poveste, če je vaš otrok imel ali ima resno bolezen srca (glejte ''Opozorila in previdnostni ukrepi'').
Patients who develop a new infection while undergoing treatment with Hulio, should be monitored closely and undergo a complete diagnostic evaluation. 
Bolnike, pri katerih se med zdravljenjem z zdravilom Hulio pojavi nova okužba, je treba natančno nadzirati, pri njih je treba izvesti popolno diagnostično obravnavo.
Adalimumab, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II. 
Uporabo adalimumaba 40 mg vsak drugi teden so pri bolnikih z zmernim do hudim aktivnim psoriatičnim artritisom proučili v dveh s placebom kontroliranih študijah, študijah psoriatičnega artritisa I in II.
The conduct and results of these tests should be recorded on child's Patient Reminder Card. 
Izvedbo in rezultate teh preiskav je treba zabeležiti na otrokovi opozorilni kartici za bolnika.
• Hulio should only be used during a pregnancy if needed. 
Zdravilo Hulio se lahko uporablja med nosečnostjo le v primeru, da je to potrebno.
When combining controlled portions of these trials and ongoing and completed open label extension studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439 patient-years of therapy, the observed rate of malignancies, other than lymphoma and nonmelanoma skin cancers is approximately 8.5 per 1,000 patient years. 
Če vzamemo skupaj kontrolirane dele teh preskušanj ter potekajoče in zaključene podaljšane odprte študije z medianim trajanjem približno 3,3 leta s 6427 bolniki in več kot 26439 bolnikov-let zdravljenja, je ugotovljeni delež malignomov (razen limfoma in nemelanomskih kožnih rakov)
• abnormal blood results; 
• nenormalne vrednosti krvnih preiskav;
The percent of adalimumab-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA studies I, II and III. 
Odstotek bolnikov, zdravljenih z adalimumabom, ki so dosegli odziv ACR 20, 50 in 70, se je v študijah revmatoidnega artritisa I, II in III skladal.
A modified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid arthritis), was used. 
Za oceno so uporabili modificirani celotni seštevek po Sharpu (modified Total Sharp Score, mTSS), ki je vključil distalne interfalangealne sklepe (tj. Ni bil enak TSS, ki se uporablja za revmatoidni artritis).
ACR 20 week 12 week 24 
ACR 20 12. teden 24. teden
A total of 76.5% (218/285) of patients who entered the retreatment period had a response of PGA “clear” or “minimal” after 16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively). 
Od bolnikov, deležnih ponovnega zdravljenja, jih je skupno 76,5 % (218/285) po 16 tednih ponovnega zdravljenja imelo odziv PGA ''čisto'' ali ''minimalno'', ne glede na to, ali je med prenehanjem uporabe prišlo do relapsa (69,1 % [123/178] bolnikov, pri katerih je med prenehanjem uporabe prišlo do relapsa, in 88,8 % [95/107] tistih, pri katerih ni prišlo do relapsa).
A 40 mg paediatric vial is available for patients who need to administer less than the full 40 mg dose. 
40 mg viala za otroke je na voljo bolnikom, ki jim je treba dati manjši odmerek od polnega 40 mg odmerka.
Peel the cover off the vial adapter package but DO NOT take the adapter out of the package. 
Odlepite prekrivno folijo z ovojnine adapterja za vialo, vendar adapterja NE vzemite iz ovojnine.
Be careful to insert the needle so that it will not inject into your fingers holding the injection site. 
Pazite, da iglo zabodete tako, da zdravila ne boste injicirali v prste, ki držijo injekcijsko mesto.
It is important to tell your doctor if you have had or have a serious heart condition (see “Warnings and precautions”). 
Pomembno je, da zdravniku poveste, če ste imeli ali imate kakšno resno bolezen srca (glejte ''Opozorila in previdnostni ukrepi'').
Put the used syringe, needle, vial and vial adapter in a sharps disposal container after use. 
Uporabljeno brizgo, iglo, vialo in adapter za vialo po uporabi odložite v vsebnik za odlaganje ostrih predmetov.
Hulio is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. 
Zdravilo Hulio je indicirano za zdravljenje zmerne do hude kronične psoriaze v plakih pri odraslih bolnikih, ki so kandidati za sistemsko zdravljenje.
79 (73.1) a, b a p<0.001 adalimumab vs. placebo b p<0.001 adalimumab vs. methotrexate c p<0.01 adalimumab vs. placebo d p<0.05 adalimumab vs. methotrexate 
79 (73,1)a, b a p < 0,001 adalimumab v primerjavi s placebom b p < 0,001 adalimumab v primerjavi z metotreksatom c p < 0,01 adalimumab v primerjavi s placebom d p < 0,05 adalimumab v primerjavi z metotreksatom
Attach the needle to the syringe by inserting the syringe tip into the yellow syringe connector on the needle. 
Namestite iglo na brizgo tako, da konico brizge vstavite v rumeni konektor za brizgo na igli.
1 sterile vial adapter 2 alcohol pads 
1 sterilen adapter za vialo 2 alkoholna zloženca
• DO NOT over-tighten. 
• NE PRIVIJTE je preveč.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Hulio. 
Vsem bolnikom je treba naročiti, naj nemudoma poiščejo zdravniško pomoč, če se jim med uporabo zdravila Hulio pojavijo znaki in simptomi krvnih diskrazij (npr. trajno zvišana telesna temperatura, podplutbe, krvavitve, bledica).
• nerve disorders (such as inflammation of the optic nerve to the eye, and Guillain-Barré syndrome, a condition that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body); 
• bolezni živčevja (kot je vnetje vidnega živca v očesu in Guillain-Barréjev sindrom, stanje, ki lahko povzroči šibkost mišic, nenormalna občutenja, mravljinčenje v rokah in zgornjem delu telesa);
Physicians should exercise caution when considering the use of Hulio in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications. 
Pri odločanju za uporabo zdravila Hulio je potrebna previdnost pri bolnikih z anamnezo ponavljajoče se okužbe ali z osnovnimi boleznimi, ki lahko zvečajo nagnjenost k okužbam, vključno s sočasno uporabljenimi imunosupresivnimi zdravili.
Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an openlabel extension trial, where adalimumab was given for at least an additional 108 weeks. 
Bolniki, ki so sodelovali v študijah psoriaze 2. in 3. faze, so bili primerni za vključitev v odprto podaljšano preskušanje, v katerem so adalimumab prejemali vsaj še dodatnih 108 tednov.
• inflammation of blood vessels in the skin; 
• vnetje krvnih žil v koži;
What Hulio contains - The active substance is adalimumab. 
Kaj vsebuje zdravilo Hulio - Učinkovina je adalimumab.
1 sterile vial adapter 
1 sterilen adapter za vialo
Hulio 40 mg solution for injection in pre-filled syringe EU/1/18/1319/001 
Hulio 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/18/1319/001
Keep the pen held at a 90° angle to the injection site, and with the Viewing Window visible to you. 
Injekcijski peresnik držite pod kotom 90° na injekcijsko mesto in tako, da vidite kontrolno okence.
Patients treated with adalimumab had significantly reduced risk of disease flare during the initial 12 weeks of treatment. 
Bolniki, zdravljeni z adalimumabom, so imeli statistično pomembno zmanjšanje tveganja novega zagona bolezni v začetnih 12 tednih zdravljenja.
Among patients whose adalimumab treatment was withdrawn at week 12 in Studies HS-I and HS-II, the HiSCR rate 12 weeks after re-introduction of adalimumab 40 mg weekly returned to levels similar to that observed before withdrawal (56.0 %). 
Med bolniki, pri katerih je bilo zdravljenje z adalimumabom ukinjeno v 12. tednu v študijah HS-I in HS-II, se je po ponovni uvedbi adalimumaba 40 mg enkrat na teden raven kliničnega odziva (HiSCR) v 12. tednu vrnila na podobno raven, kot so jo opazili pred ukinitvijo (56,0 %).
673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an inadequate response to  2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into the open-label period of Study nr-axSpA II during which they received adalimumab 40 mg eow for 28 weeks. 
673 bolnikov z aktivnim nr-axSpA (srednja vrednost aktivnosti bolezni [BASDAI] je bila 7,0), ki so nezadostno reagirali na ≥ 2 NSAID ali niso prenašali NSAID ali s kontraindikacijo za NSAID, je bilo vključenih v odprto fazo študije nr-axSpA II, v kateri so prejemali adalimumab 40 mg vsak drugi teden 28 tednov.
• If you are about to have surgery or dental procedures, tell your doctor that you are taking Hulio. 
• Če boste imeli kirurški poseg ali poseg na zobeh, povejte svojemu zdravniku, da jemljete zdravilo Hulio.
In RA study III, most subjects who achieved improvement in physical function and continued treatment maintained improvement through week 520 (120 months) of open-label treatment. 
V študiji revmatoidnega artritisa III se je pri večini bolnikov, ki so dosegli izboljšanje telesne funkcije in so nadaljevali zdravljenje, to izboljšanje ohranilo do 520. tedna (120. meseca) odprtega zdravljenja.
Hulio packs should be stored in the fridge (between 2 to 8°C) until needed for use. 
Pakiranje zdravila Hulio shranjujte v hladilniku (pri temperaturi od 2 do 8 °C), dokler ga ne boste uporabili.
In the open-label extension, improvement in the signs and symptoms was maintained with adalimumab therapy through week 156. 
Pri odprti podaljšani študiji se je pri zdravljenju z adalimumabom izboljšanje znakov in simptomov ohranjalo do 156. tedna.
Note: P# = Placebo (Number of Events/Number at Risk); A# = adalimumab (Number of Events/Number at Risk). 
Opomba: P# = Placebo (število dogodkov/število rizičnih preiskovancev); A# = adalimumab (število dogodkov/število rizičnih preiskovancev).
Based on the observed data approach, 222 (80.4%) were in quiescence (no active inflammatory lesions, AC cell grade ≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg per day, and 184 (66.7 %) were in steroid-free quiescence. 
Na osnovi pristopa z opaženimi podatki je bilo 222 (80,4 %) bolnikov v remisiji (brez aktivnih vnetnih lezij, ocena celic sprednje očesne komore ≤ 0,5+, motnost steklovine ≤ 0,5+) ob sočasnem jemanju steroidov v odmerku 7,5 mg na dan in pa 184 bolnikov (66,7 %), ki so bili v remisiji in brez steroidov.
INFORMATION IN BRAILLE Hulio 40 mg/0.8 ml 
PODATKI V BRAILLOVI PISAVI Hulio 40 mg/0,8 ml
It is very important that you tell your child's doctor if he/she have ever had tuberculosis, or if he/she have been in close contact with someone who has had tuberculosis. 
Zelo pomembno je, da zdravniku poveste, če je vaš otrok kadar koli imel tuberkulozo ali je bil v tesnem stiku s kom, ki jo je imel.
Patients participating in Studies HS-I and HS-II were eligible to enrol into an open-label extension study in which adalimumab 40 mg was administered every week. 
Bolniki, vključeni v študiji HS-I in HS-II, so bili primerni za vključitev v odprto podaljšano študijo, v okviru katere so prejemali adalimumab 40 mg vsak teden.
Table 29: Time to Treatment Failure in Studies UV I and UV II 
Preglednica 29: Čas do neuspeha zdravljenja v študijah UV I in UV II Analiza
Flip down the pink needle cover and remove the needle cap by pulling it straight up. 
Rožnati pokrovček igle obrnite navzdol in odstranite pokrovček igle tako, da ga potegnete naravnost navzgor.
• DO NOT hold the syringe by the white plunger rod. 
• NE DRŽITE brizge za beli nosilec bata.
• Tell your doctor if you reside or travel in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are common. 
• Zdravniku povejte, če živite na območju ali potujete v predele, kjer so pogoste glivične okužbe, npr. histoplazmoza, kokcidioidomikoza ali blastomikoza.
Tell your child's doctor if your child is taking azathioprine or mercaptopurine with Hulio. 
Povejte otrokovemu zdravniku, če vaš otrok prejema azatioprin ali merkaptopurin sočasno z zdravilom Hulio.
Each single pack containing 1 vial (0.8 ml sterile solution), 1 empty sterile injection syringe, 1 sterile needle, 1 sterile vial adapter and 2 alcohol pads. 
Vsako enojno pakiranje vsebuje 1 vialo (0,8 ml sterilne raztopine), 1 prazno sterilno injekcijsko brizgo, 1 sterilno iglo, 1 sterilen adapter za vialo in 2 alkoholna zloženca.
Each vial contains 38.2 mg sorbitol (E420). 
Ena viala vsebuje 38,2 mg sorbitola (E420).
Each vial contains one 40 mg dose of adalimumab. 
Ena viala vsebuje en 40 mg odmerek adalimumaba.
• DO NOT use the pen if it has been dropped onto a hard surface. 
• NE uporabljajte injekcijskega peresnika, če je padel na trdo površino.
Tell your doctor if you are taking azathioprine or mercaptopurine with Hulio. 
Povejte zdravniku, če jemljete azatioprin ali merkaptopurin sočasno z zdravilom Hulio.
If you have rheumatoid arthritis and you do not receive methotrexate with your Hulio therapy, your doctor may decide to give you 40 mg adalimumab every week or 80 mg every other week. 
Če imate revmatoidni artritis in hkrati z zdravilom Hulio ne dobivate metotreksata, vam bo zdravnik morda predpisal 40 mg adalimumaba vsak teden ali 80 mg vsak drugi teden.
• immune disorders that could affect the lungs, skin and lymph nodes (most commonly as a condition called sarcoidosis); 
• imunske bolezni, ki lahko prizadenejo pljuča, kožo ali limfne vozle (najpogosteje kot stanje,
• DO NOT use the pre-filled syringe if dropped after uncapping. 
• NE uporabljajte napolnjene injekcijske brizge, če vam je padla, potem ko ste odstranili pokrovček.
Among those, 154 patients (90.6%) had ACR 20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70 responses. 
Med temi je 154 bolnikov (90,6 %) imelo odziv 20 po ACR; 127 bolnikov (74,7 %) je imelo odziv 50 po ACR in 102 bolnika (60,0 %) sta imela odziv 70 po ACR.
Table 19: Ps Study IV Efficacy Results at 16, 26 and 52 weeks 
Preglednica 19: Študija pri psoriazi IV Rezultati učinkovitosti po 16, 26 in 52 tednih
If you stop using Hulio 
Če ste prenehali uporabljati zdravilo Hulio
It should be injected into the thigh or abdomen. 
Injicirati ga je treba v stegno ali trebuh.
After 16 weeks of therapy, patients who achieved at least a PASI 75 response (PASI score improvement of at least 75% relative to baseline), entered period B and received open-label 40 mg adalimumab every other week. 
Po 16 tednih zdravljenja so bolniki, ki so dosegli vsaj odziv PASI 75 (izboljšanje ocene PASI za vsaj 75 % glede na izhodišče), vstopili v obdobje B, v katerem so odprto dobivali 40 mg adalimumaba vsak drugi teden.
Hulio is used to treat Crohn's disease in children aged 6 to 17 years. 
Zdravilo Hulio je namenjeno za zdravljenje Crohnove bolezni pri otrocih, starih od 6 do 17 let.
Prescribers should exercise caution in considering the use of Hulio in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of Hulio should be considered if any of these disorders develop. 
Pri odločanju za uporabo zdravila Hulio pri bolnikih z že prej obstoječimi ali nedavno nastalimi demielinizirajočimi boleznimi osrednjega ali perifernega živčevja je potrebna previdnost; če se razvije katera od teh bolezni, je treba razmisliti o prenehanju zdravljenja z zdravilom Hulio.
Greater improvements at week 12 from baseline compared to placebo were demonstrated in skinspecific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as measured by the physical component summary score of the SF-36 (Study HS-I). 
Večje izboljšanje v 12. tednu so pokazali glede na izhodiščno vrednost v primerjavi s placebom glede z zdravjem povezane kakovosti življenja, specifične za kožo, merjene z dermatološkim indeksom kakovosti življenja (''Dermatology life quality index'' (DLQI), v študijah HS-I in HS-II), glede bolnikovega splošnega zadovoljstva z zdravljenjem z zdravilom, merjenega z vprašalnikom o zadovoljstvu z zdravljenjem z zdravilom (''Treatment Satisfaction Questionnaire - medication'' (TSQM), v študijah HS-I in HS-II), in glede telesnega zdravja, merjenega s seštevkom telesnih komponent v vprašalniku SF-36 (''Short Form Health Survey'' (SF-36) v študiji HS-I).
The observed rate of nonmelanoma skin cancers is approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per 1,000 patient years. 
Ugotovljeni delež nemelanomskih kožnih rakov je približno 9,6 na 1000 bolnikov-let, ugotovljeni delež limfomov pa približno 1,3 na 1000 bolnikov-let.
• Do not give Hulio to children with hidradenitis suppurativa below the age of 12 years. 
• Zdravila Hulio ne smete dati otroku s hidradenitis suppurativa, če je star manj kot 12 let.
Peel the clear plastic just far enough to expose the yellow connector, but DO NOT take the needle out of the package. 
Odlepite prozorno plastiko ravno toliko, da odkrijete rumeni konektor, vendar igle NE vzemite iz ovojnine.
There are no data available comparing adalimumab and MTX beyond 16 weeks of therapy. 
Podatkov za primerjavo adalimumaba in metotreksata za več kot 16-tedensko zdravljenje ni.
Hulio can slow down the damage to the cartilage and bone of the joints caused by the disease and improve physical function. 
Zdravilo Hulio lahko upočasni okvaro sklepnega hrustanca in kosti, ki jo povzroča ta bolezen, in izboljšuje telesno delovanje.
In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the adalimumab treated patients and 1.46 per patient year in the placebo and active control-treated patients. 
V kontroliranih osrednjih preskušanjih pri odraslih in otrocih je bil delež okužb 1,51 na bolnikov-let med bolniki, ki so prejemali adalimumab, in 1,46 na bolnikov-let med bolniki, ki so prejemali placebo oziroma primerjalno zdravilo.
For patients who are prescribed a dose less than 40 mg, Hulio 40 mg/0.8 ml solution for injection in a vial (available from your pharmacist) should be used. 
Bolniki, ki jim je predpisan manjši odmerek od 40 mg, naj uporabijo Hulio 40 mg/0,8 ml raztopino za injiciranje v viali (na voljo pri farmacevtu).
SPARCC MRI Spined,j a Assessment of Spondyloarthritis International Society b Bath Ankylosing Spondylitis Disease Activity Index c Ankylosing Spondylitis Disease Activity Score d mean change from baseline e n=91 placebo and n=87 adalimumab f high sensitivity C-Reactive Protein (mg/L) g n=73 placebo and n=70 adalimumab h Spondyloarthritis Research Consortium of Canada i n=84 placebo and adalimumab j n=82 placebo and n=85 adalimumab 
Disease Activity Score) d povprečna sprememba od začetka zdravljenja e n = 91 placebo in n = 87 adalimumab f hs-CRP = C-reaktivni protein z veliko občutljivostjo (high sensitivity C-Reactive Protein) (mg/l) g n = 73 placebo in n = 70 adalimumab h SPARCC = kanadski raziskovalni konzorcij za spondiloartritis (Spondyloarthritis Research
How to use Hulio 
Kako uporabljati zdravilo Hulio
• Tell your child's doctor if you reside or travel in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are common. 
• Otrokovemu zdravniku povejte, če živite na območju ali potujete v predele, kjer so pogoste glivične okužbe, npr. histoplazmoza, kokcidioidomikoza ali blastomikoza.
• hepatosplenic T-cell lymphoma (a rare blood cancer); 
• jetrnovranični limfom celic T (redka oblika krvnega raka);
Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the adalimumab group experienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively). 
Približno dvakratni delež bolnikov v skupini, ki je prejemala placebo, je v primerjavi s tistimi, ki so bili v skupini z adalimumabom, v prvih 12 tednih študij HS-I in HS-II doživel poslabšanje abscesov (23,0 % v primerjavi z 11,4 %, v tem zaporedju) in fistul z izcedkom (30,0 % v primerjavi s 13,9 %, v tem zaporedju).
Insert the syringe tip into the vial adapter and twist it clockwise until firmly attached. 
Konico brizge vstavite v adapter za vialo in jo sukajte v smeri urnega kazalca, dokler ni trdno nameščena.
RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. 
V študiji revmatoidnega artritisa II je bilo ocenjenih 544 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno.
Psoriasis Study II (CHAMPION) compared the efficacy and safety of adalimumab versus methotrexate and placebo in 271 patients. 
Študija psoriaze II (CHAMPION) je primerjala učinkovitost in varnost adalimumaba v primerjavi z metotreksatom in placebom pri 271 bolnikih.